BFSG LLC’s 4D Molecular Therapeutics FDMT Stock Holding History

BFSG LLC’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500	Closed	-$10.5K	–	643
2024 Q2	$10.5K	Hold	500	–	–	﹤0.01%	475
2024 Q1	$15.9K	Sell	500 -1,000	-67%	-$25.5K	﹤0.01%	449
2023 Q4	$30.4K	Buy	+1,500	New	+$19.7K	﹤0.01%	391

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFSG LLC's FDMT Position: Q3 2024 in Review

BFSG LLC sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 500 shares — an estimated $10.5K sold.

BFSG LLC first reported a position in FDMT in Q4 2023 and held it in 3 quarters. The position peaked at $30.4K in Q4 2023. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

BFSG LLC reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
BFSG LLC sold 500 4D Molecular Therapeutics shares in Q3 2024, an estimated $10.5K.
BFSG LLC first reported a position in 4D Molecular Therapeutics in Q4 2023 and held it in 3 quarters.
BFSG LLC's 4D Molecular Therapeutics position peaked at $30.4K in Q4 2023.
140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on BFSG LLC's 13F filing for Q3 2024, filed 16 Oct 2024.